Adolescents and young children taking the attention deficit-hyperactivity medication called Strattera, face a serious risk. Eli Lilly and Co., the company that produces and distributes Strattera, has been order by U.S. regulators to include a “black box” warning on the drug containers. The warning must inform the consumer that in taking this drug, Strattera leads to an increase in suicidal thoughts among adolescents and children. This can make one question whether or not it is really necessary in some cases to put an individual’s child on an attention deficit-hyperactivity drug in the first place.